Latent TB infection (LTBI) occurs when a person is infected with Mycobacterium TB, but does not have active TB. Unlike active TB, LTBI is not contagious. Approximately 10% of people with LTBI will go on to develop active TB. This is particularly true in people with a suppressed immune system or advancing age. The identification and treatment of people with latent TB is therefore an important part of controlling TB.
The goal of the IMPAACT4TB (Increasing Market and Public health outcomes through scaling up Affordable Access models of short Course preventive therapy for TB) project is to reduce TB incidence and deaths among people living with HIV (PLHIV) (15-49 years) and child contacts through sustainable implementation of affordable, quality-assured 3HP.
3HP is a short-course regimen of isoniazid and rifapentine weekly for three months for treatment of LTBI. The outcomes of the project are to: increase the number of PLHIV and child contacts under the age of five years starting treatment with affordable, quality-assured 3HP; and contribute to revising WHO preventive therapy management guidelines based on evidence generated from this project.
During the last quarter of 2019 agreement was reached on the price of 3HP. The agreement brings a one-month supply of rifapentine tablets down from US$15 to US$5 per patient pack for the public sectors of high-burden TB countries. This agreement paved the way for countries to procure the drugs and ensure readiness for treatment of patients starting early 2020 with 3HP.
Countries implemented by KNCV: Ethiopia, Indonesia, Malawi and Tanzania